Clene's CNM-Au8 Shows Promise in Parkinson's Disease Preclinical Study
Clene Inc. presented preclinical data demonstrating its investigational drug CNM-Au8 improves mitochondrial function and reduces inflammation in Parkinson's disease models, potentially offering a new neuroprotective treatment approach.
Clene Inc. (NASDAQ: CLNN) has unveiled new preclinical findings indicating that its investigational drug CNM-Au8 significantly improves cellular health in Parkinson's disease models. The data, presented at the Michael J. Fox Foundation H2 Therapeutics Stewardship Meeting, showed that CNM-Au8 enhanced mitochondrial function, reduced inflammation, and restored cellular metabolism in dopaminergic neuron models of Parkinson's disease.
The study, conducted in collaboration with the Salk Institute and supported by Michael J. Fox Foundation funding, revealed that CNM-Au8 corrected metabolic imbalances and normalized dysregulated gene expression in Parkinson's disease neurons. The treatment also demonstrated a favorable safety profile with no observed toxicity in the tested models, suggesting potential as a neuroprotective therapy for both familial and sporadic forms of Parkinson's disease.
CNM-Au8 represents a first-in-class therapeutic approach that targets mitochondrial function and the NAD pathway while reducing oxidative stress. The drug's mechanism of action focuses on improving central nervous system cell survival and function, addressing fundamental cellular dysfunctions associated with neurodegenerative diseases. For more information about the company's research, visit https://www.clene.com.
The findings contribute to the growing body of evidence supporting mitochondrial-targeted therapies for neurodegenerative conditions. Parkinson's disease affects millions worldwide and currently lacks disease-modifying treatments, making these preclinical results particularly significant for the neurology research community. The full research details are available through the company's newsroom at https://ibn.fm/CLNN.